Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nuvectis Pharma, Inc. - Common Stock
(NQ:
NVCT
)
5.980
-0.170 (-2.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nuvectis Pharma, Inc. - Common Stock
< Previous
1
2
3
4
Next >
More Than $3M Bet On Asana? Check Out These 3 Stocks Insiders Are Buying
July 11, 2023
Although US stocks closed higher on Monday, there were a few notable insider trades.
Via
Benzinga
$1M Bet On Children's Place? Check Out These 3 Stocks Insiders Are Buying
July 07, 2023
Although US stocks closed lower on Thursday, there were a few notable insider trades.
Via
Benzinga
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
June 20, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Over $2M Bet On This Financial Services Stock? Check Out These 3 Stocks Insiders Are Buying
June 20, 2023
Although US stocks closed lower on Friday, there were a few notable insider trades.
Via
Benzinga
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
May 15, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
April 27, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
April 27, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
April 18, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
April 10, 2023
Phase 1b study builds on highly consistent preclinical and Phase 1a data
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
March 17, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
March 10, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
February 23, 2023
Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, superior to treatment with cisplatin
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
January 04, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
December 01, 2022
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
October 03, 2022
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Formation of a Scientific Advisory Board
September 28, 2022
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
July 27, 2022
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
July 27, 2022
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
Via
Benzinga
5 Best Performing Micro-Cap Stocks Through the First Half of 2022
July 05, 2022
The first half of 2022 is finally in the books and it could not have come sooner. Major U.S. indices
Via
Spotlight Growth
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
July 13, 2022
Upgrades
Via
Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
June 21, 2022
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...
Via
Benzinga
Nuvectis Pharma Gets FDA Nod For Initial-Stage Ovarian Cancer Study
June 21, 2022
The U.S. Food and Drug Administration (FDA) cleared Nuvectis Pharma’s (NASDAQ: NVCT) Investigational New Drug Application (IND) for NXP800, which includes the Phase 1 clinical trial protocol.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 27, 2022
Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares moved upwards by 9.9% to $1.0 during Wednesday's after-market session. The company's market cap stands at $15.0 million.
Via
Benzinga
51 Biggest Movers From Yesterday
April 07, 2022
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies and Hyundai Motor Company entered into...
Via
Benzinga
82 Biggest Movers From Yesterday
June 15, 2022
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 06, 2022
Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 32.4% to $7.43 during Wednesday's regular session. Sunshine Biopharma's stock is trading at a volume of 46.8...
Via
Benzinga
92 Biggest Movers From Friday
May 09, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...
Via
Benzinga
83 Biggest Movers From Yesterday
May 06, 2022
Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results.
Via
Benzinga
80 Biggest Movers From Yesterday
May 04, 2022
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX Therapeutics Inc. (NASDAQ: XRTX) gained 59.1% to...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.